Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seviteronel in Castration-Resistant Prostate Cancer
NCT02361086Phase 2Completed
- Sponsor
- Innocrin
- Start
- Jun 2014
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of seviteronel in castration-resistant prostate cancer (CRPC), sponsored by Innocrin. Started Jun 2014; status: completed.
02
Drugs
seviteronel
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02361086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02361086.